2018 FDA Policy Priorities Plan on Compounding Drugs

  • 0
  • November 15, 2018

The FDA recommends that compounded drugs not be used when FDA-approved alternatives exist. In its 2018 Compounding Policy Priorities Plan, the FDA cites several risks associated with compounded drugs and shares examples of cases in which compounded products have caused harm to patients.

Read the FDA’s full policy plan here

CaroSpir is the first and only FDA-approved oral suspension of the potassium-sparing diuretic spironolactone. Please visit www.CaroSpir.com to learn more.